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Abstract: In the present study, we describe the biochemical properties and effects of nitric 
oxide (NO) in intact and dysfunctional arterial and venous endothelium. Application of the 
NO electrochemical sensor in vivo and in vitro in erythrocytes of healthy subjects and 
patients with vascular disease are reviewed. The electrochemical NO sensor device applied 
to human umbilical venous endothelial cells (HUVECs) and the description of others NO 
types of sensors are also mentioned. 
Keywords: endothelium erythrocyte nitric oxide; microelectrode 
 
1. Introduction 
Nitric oxide (NO) is a soluble gas synthesized from L-arginine by the enzyme nitric oxide synthase 
(NOS) [1]. Three isoforms of NOS have been described, namely the neuronal (nNOS or NOSI), the 
inducible (NOSII or iNOS), and the constitutive endothelial form (eNOS or NOSIII), which was the 
first to be discovered [1–3]. Both neuronal and endothelial enzymes are activated by the calcium and 
calmodulin complex, and the inducible form binds to calmodulin but is independent of intracellular 
calcium concentration [4]. These isoenzymes are flavoproteins that act on L-arginine, in the presence of 
oxygen and NADPH, and require tetrahydrobiopterin (BH4). In the absence of BH4, a superoxide 
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anion is formed instead of NO [5]. The isoform eNOS is also expressed in platelets and in cardiac 
myocytes [6,7]. 
NO produced in the endothelial cell diffuses to the lumen where it is captured by red blood cells 
(RBC) and transferred into muscle cells where it induces relaxation, eliciting vasodilation. In this 
mechanism, guanosine 3′,5′-cyclic monophosphate (cGMP), formed from guanosine 5′-triphosphate 
(GTP) by the action of guanylate cyclase (GC), is activated by NO [3]. cGMP modulates the myosin 
light chain (MLC) phosphatase positively and MLC kinase negatively, resulting in the dephosphorylation 
of MLC with subsequent muscle relaxation [3]. NO-induced vasodilation is dependent on hematocrit, 
blood flow and the hemoglobin free concentration in the circulation [8]. The presence of free hemoglobin 
reduces vasodilation in pig coronary arteries, induced previously by serotonin or by shear stress [8]. 
The increase in vascular permeability, inhibition of platelet aggregation, platelet adhesion, proliferation, 
and migration of smooth muscle cells are effects mediated by NO-dependent cGMP [9]. 
The intact vascular endothelium establishes a dynamic interface between blood and tissues, allowing 
gas and metabolites exchanges and participates in hemostasis, in thrombosis, and in inflammatory and 
anti-inflammatory mechanisms [10,11]. The phenotype of endothelial cells is dependent on the 
location in the vascular field and presents specific responses to various stimuli [11]. Endothelial cells 
of post capillary venules respond to inflammatory signals and those in the arterial vascular network 
release vasoactive substances into the blood [11]. Among the endogenous vasoactive compounds, 
acetylcholine (ACh) acts like an autocrine or paracrine signal in endothelial cells, stimulating eNOS, 
with the formation of NO [1,3]. 
The rapid time course of these events and the short half-life of NO includes several methods, based 
on electrochemical, chemiluminiscent, and spectrophotometric principles, which have been developed 
in order to measure NO or its derivative molecules. The method must be sensitive for in situ 
measurements. NO microsensors have been developed for real time assessment in vivo [12–14]. The real 
time measurement of NO, in response to stimuli and drugs, will contribute to therapeutic advances in 
endothelial dysfunction. 
2. Nitric Oxide Sensors 
The utilization of NO sensors allows the quantification of NO concentration ranging from subnamolar 
to micromolar values [15]. Usually, the biosensor consists of a biorecognition element, a signal transducer 
and a detector. The electrochemical sensors are, for now, the more reliable tool for NO detection in 
real time. They operate via the application of a potential at the electrode surface positive or negative to 
electrochemically oxidize or reduce NO. The resulting transfer of electrons is measured as a current 
proportional to the NO concentration. 
Our studies of NO measurement in human erythrocytes suspensions were performed with the 
amiNO-IV sensor (Innovative Instruments Inc., Tampa, FL, USA) [16]. The figure of the electrode can 
be seen in the webpage: http://www.2in.com. 
The sensor has a sharp metallic tip completely covered with a series of membrane, including a gas 
permeable membrane. The ―amiNO‖ series of nitric oxide sensors, with tip diameter ranges of 7 µm to 
600 µm, do not require an external reference electrode has high sensitivity abolishing the errors due to 
baseline drift associated with temperature changes and they are shielded from electrical noise. They 
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were designed for in vivo and large surfaces (cultured cells), works with the inNO-T meter with easy 
calibration procedures. The inNO-Tcombine both a NO configured potentiostat and a software controlled 
data acquisition system included in one battery powered unit. The ―amiNO‖ series sensor is covered 
with a triplecoat gas permeable membrane to guarantee selectivity and fast response time. The NO 
diffuses through the membrane and is then oxidized at the working platinum electrode, resulting in an 
electric current. The redox current is proportional to the NO concentration outside the membrane and 
is continuously monitorized with an inNO-TM software (version 1.9 supplied by Innovative Instruments 
Inc.) installed on a PC computer. The calibration curve and its representative appear in Figure 1 of our 
published previous work [16]. Briefly, the sensor is calibrated by a simple, economical, and a reliable 
chemical reaction for NO production. This reaction is based on the conversion of nitrite to nitric oxide 
in acidic solution in the presence of iodide ion. The reaction has a ratio of one to one, meaning that the 
amount of NO produced in this reaction equal to the amount of nitrite added. 
The amino-IV sensor with its NO-permeable membrane triplecoat avoid a broad range of interfering 
molecules forming during the electrochemical reaction of NO on metal surfaces at positive electrode 
potentials via electron oxidation mechanism: Alloys of platinum [17], carbon fibber [18], and glassy 
carbon [19] are materials additionally developed to cover the surface of the electrodes that show 
variable sensitivity, selectivity, and signal stability [20–23]. 
The most common modes of electrode operate are by electroreduction of NO, direct electrooxidation 
of NO and catalytic electrooxidation of NO [20–23]. The electroreduction has the advantage to 
eliminate the interfering molecules but, at variance, has low sensitivity and pH and electrode surface 
characteristics dependence [24–26]. In these types of electrode oxygen molecules interferes and is a 
problem in biological applications due to its scavenger properties as mentioned in the previous 
sections. In the electrode operate by electroreduction of NO the introduction of a transition metal or 
metalloproteins such as haemoglobin have proven to be useful to improve sensitivity and measurements 
of NO at low range of sub-micromolar concentrations [24,25].  
In the electrode operate by the direct electrooxidation of NO there are broad types of sensors  
with different electrode material composition of NO-selective membranes, and diverse diameters 
originating a large variety of values of limit of detection ranging from 0.083 nM to 75 nM [27,28].  
Thus, they are dependent on the permselective membrane. In the type of electrode that operates by 
catalytic electrooxidation of NO a redox mediator for example a metalloporphyrins immobilized on the 
electrode surface or incorporated in a polymer is utilized [18]. The function of the mediator is to acts 
as catalysts for the oxidation of NO. However, non-porphyrin complexes have showed also similar 
results [29]. 
The sensors descried in the literature to measure NO in solution are classified as belonging to three 
classes as follows: Shibuki-style; solid permselective; and solid catalytic and their characteristics and 
composition are summarized in the Table 1 [20,30]. The first one style of sensor determine NO by 
electrooxidation and the others two by electrooxidation or electroreduction [20,30]. All the three types 
of sensors integrate a reference electrode that is within the electrolyte filling solution in the Shibuki-style. 
The catalytic style comprise a mediator (metalloporphyrins or metal phtalocyanines) for catalyze the 
oxidation or reduction of NO. 
While sensors applied to in vivo, NO measurements in blood has confined in humans [31] others for 
determinations of NO released in biological tissues like heart, brain, or lung are used only in animal 
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experimental models [32–34]. For example an electrochemical microsensor has been inserted into a 
human hand vein to detect NO in blood vessels of healthy persons [31]. It is confirmed in vivo, in human 
beings, that the endothelium derived relaxing factor is the NO from the stimulation with ACh [31].  
Table 1. Characteristics and composition of nitric oxide sensors. 
Sensor class Internal filling solution Composition Sensitivity Miniturization 
Shibuki-style Electrolyte Platinum and silver 
Variable over time and 
between sensors 
Not possible 
Solid 
permselective 
Eliminated Carbon 
Multiple membranes 
discriminate 
interference molecules 
Possible 
Solid catalytic Eliminated 
Mediator incorporated in 
electrode surface or in 
permselective membrane 
Minimize interference 
molecules 
Possible 
3. Nitric Oxide in Arterial Endothelium 
The vasoactive function of ACh could be compromised by the erythrocyte aggregation tendency 
that is increased in a few vascular disorders including hypercholesterolemia, arterial hypertension, 
acute myocardial infarction, and diabetes [35–38]. 
The vascular endothelium is dysfunctional when it is not able to regulate its tone to maintain 
structural organization contributing to the installation and progression of hypertension and 
atherosclerosis [11,39]. These arterial diseases are considered cardiovascular risk factors and are 
associated with stimulation of NAPH oxidase and generation of reactive oxygen species [40,41]. 
Dismutation of the superoxide anion hydrogen peroxide is formed, stimulating the expression of eNOS 
that was verified to be associated with these two cardiovascular risk factors [42,43]. In this case, NO 
production is insufficient to overcome consumption by superoxide anion with the generation of 
peroxynitrite that deregulates (uncouples) eNOS, switching to the production of superoxide anion 
instead of NO [44].  
Vasodilation of the vessels fails to appear by lower concentrations of NO, which support platelet 
and leukocyte adhesion stimulating the inflammatory response in the pathogenesis and progression of 
atherosclerotic disease [45]. Its etiology is recognized as complicated and multi-factorial [45]. Thus, any 
manipulations of the pathway of eNOS appear to be promising treatments [46,47].  
In the composition of the atheromatous plaque there are muscle cells, macrophages that are in the 
apoptotic state and are ingested by phagocytes, which decrease the inflammatory response and plaque 
regression [48]. Pro-apoptotic functions and anti-atherogenic properties of NO are important, along 
with destabilization of the plaque, which could occur due to enhancement of muscle cell apoptosis 
induced by NO [48]. The most effective way to increase NO synthesis is by adaptation to hypoxia that 
is observed in hypertensive stage 1 patients characterized by decreased concentrations of NO [49,50]. 
Patients with grade 1 hypertension submitted to intermittent conditions of normobaric and hypoxia 
normalize blood pressure and NO synthesis [50]. 
The constant presence of hypoxia can lead to decreased synthesis of NO and in turn to the onset of 
pulmonary arterial hypertension. Inhaled ethyl nitrite has shown promising results in neonates with 
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pulmonary hypertension [51]. Inhibitors of the enzyme phosphodiesterase that catalyze the 
decomposition of cGMP may be an alternative therapy to the inhalation of NO applied in pulmonary 
hypertension [52,53]. Nitroglycerin (GTN) acts by inducing vasodilation independent of the endothelium 
and is used as a therapeutic agent in coronary artery disease with some conditions [54]. Chronic use of 
NTG regress NO levels and maintains endothelial dysfunction [54]. 
There are many exogenous compounds leading to nitric oxide availability including nitrite,  
S-nitrosothiols, N-nitroso-proteins, and iron nitrosyl complexes [55]. Nonsteroidal anti-inflammatory 
compounds (NSAID) related to derivatives of NO molecules have been synthesized to verify its 
effectiveness as NO donors and as cardioprotective agents [56]. Among the NSAIDs, aspirin derivatized 
with NO donors decreases intestinal toxicity and stimulates the eNOS enzyme in a pulsatile  
manner [56,57]. The statins, the type 1 receptor blockers of angiotensin II and estrogen, increase the 
synthesis of tetrahydrobiopterin. Statins also inhibit NADPH oxidase and protect the cofactor from 
oxidation induced by eNOS [58]. Polyphenols present in red wine, by inhibiting the overexpression of 
NAPH oxidase reduce oxidative stress and protect endothelial cells by maintenance of the basal level 
of NO, reducing the tendency of peroxinite formation [59]. 
Patients with depression have diminished levels of the natural substrate of NO, L-arginine; it is 
estimated that depression can lead to the onset of coronary artery disease (CAD) [60]. However, 
whether supplementation of L-arginine provides improvement for CAD is unknown [60]. It is known 
that a diet with high levels of black beans, endive, and spinach can be a source of nitrate that gives 
nitrites in the salivary-enteric circulation, following a sequence of catalysis reaction involving acidic 
oxides of nitrogen that lead to NO in the blood and tissues [61]. There is evidence that a diet rich in 
vegetables and supplements of nitrates decreases blood pressure and the risk of brain ischemic 
occurrences [62]. The risk of cardiovascular events in CAD is associated inversely with the catalytic 
activity of erythrocyte glutathione peroxidase [63]. In addition, published studies demonstrated the 
existence of NOS3 polymorphisms associated with some groups of patients with CAD and with groups 
of insulin-dependent diabetics who will develop CAD [64,65]. The implication of polymorphisms of 
NOS isoenzymes in the appearance of CAD requires further study. 
Recently, measurements of NO in vivo and in humans directly using an electrochemical electrode 
sensor have been developed and applied in the coronary circulation [14]. The study was performed in 
patients with dilated cardiomyophaty and in healthy controls and NO was measured in the proximal 
great cardiac vein with a catheter-type sensor [14]. The authors give a contribute for the clinical 
quantification of endothelial dys(function) by measuring in vivo endothelium availability of NO [14]. 
The determination of NO associated with the evaluation of coronary diameter and coronary blood flow 
could give useful information for the application of adjusted therapeutics. 
4. Nitric Oxide in the Venous Endothelium 
Human umbilical vein endothelial cells (HUVECs) in the presence of ACh, the natural substrate of 
acetylcholinesterase (AChE), liberate higher values of NO than basal values [66]. Variance when 
velnacrine (AChE inhibitor) was added to the HUVECS lowers values of NO than those observed for 
ACh [66]. These results were obtained using the electrochemical sensor amino-IV NO [66]. Further 
studies are needed to clarify the signal transduction mechanisms in endothelial cells under the 
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influence of activators and inhibitors of acetylchonisterase. Others biosensors for NO evaluation are 
available as described above.  
The appearance of structural changes in connective tissue, smooth muscle, and of functional changes 
in venous endothelium, defects in the microcirculatory network, and deficient supplies of nutrients in 
the venous sector are inducers of varicosity appearance [67,68]. In venous disease, the upright position 
originates a decrease of oxygen partial pressure in tissues, capillary stasis, and hypoxia that activates 
endothelial cells with increased cytoplasmic calcium. This is crucial for the release of proinflammatory 
factors (such as PAF, leukotriene B4, prostaglandins E2 and D2) [69–72]. The release of histamine and 
serotonin stimulate the migration of leukocytes to the endothelium and expression of adhesion 
molecules in both cells [73]. Moreover, endothelial cells produce cytokines (IL-1beta, IL-6, TNF alpha) 
and prothrombotic factors (von Willebrand factor) that elicit monocytes and activated T lymphocytes 
with the inflammatory response [73]. Inflammation does not occur only in the post-capillary venules, 
but also in the large veins which contributes to a better understanding of the etiology of venous 
thrombosis and pulmonary embolism [74]. Flow-mediated vasodilation is impaired in patients with 
spontaneous venous thromboembolism, which is an indicator of endothelial dysfunction [75]. 
In the venous endothelium of healthy individuals, as happens on the arterial side, there is release of 
nitric oxide which regulates and maintains venous tone [76]. The NO secretion by vascular endothelial 
cells is depending on shear stress [77]. In chronic venous insufficiency, the diameter of the vein is 
increased, decreasing shear stress and the production of NO by endothelial cells during the initial 
phase. After the expression of inducible nitric oxide synthase, higher amounts of NO are released that 
interact with the superoxide anion (produced by leukocytes and macrophages) producing peroxynitrite 
that causes tissue oxidation of chronic venous ulcers. 
The restoration of basal levels of NO is a therapeutic target for the healing of ulcers [76]. The success 
of wound healing in patients receiving monocromatic infrared energy and submitted to stretching and 
resistance exercise may be associated with increases of NO in the blood [78]. 
If heart failure is accompanied with venous vascular dysfunction, it benefits from therapeutics that 
acts on restoring venous vascular function dependent on NO [76].  
Application of an eNOS inhibitor on the venous network normalizes venous vascular resistance and 
blood pressure values in the lower limbs, although these results are still preliminary [79]. 
Hyperemia observed in the elderly with passive movement of the legs is absent in patients with 
peripheral arterial disease. This supports the hypothesis that NO is present in venous endothelial  
cells [80]. The results obtained with inhibitors of eNOS confirm this hypothesis [81]. The authors 
consider that the passive movement of the legs may become a noninvasive instrument for analyzing the 
function of the endothelial NO in venous tissue [80]. 
Endothelial function can be evaluated using non-invasive techniques including high-resolution 
ultrasonography that measures vasodilation in the radial, femoral, and brachial arteries [81].  
The vasodilation resulting from the action of vasodilators is used as a benchmark. Nitroglycerin is used 
as a diagnostic test for portal hypertension (PHT) [82]. The extent of PHT is quantified in clinical 
practice by measuring the hepatic portal vein pressure gradient [83]. In PHT, the insufficient release of 
NO from endothelial cells influences the increase of vascular resistance at the level of the intra-hepatic 
microcirculation [84,85]. There is excessive production of NO in the splanchnic circulation that must 
be accounted for when NO donors are used to reduce portal pressure [86]. Many of the studies 
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regarding the influence of NO donors on the venous vascular sector are performed in experimental 
animal models, suggesting the best treatment strategies dependent on NO can function in the resolution 
of human venous disease. 
5. Nitric Oxide in Erythrocytes 
In physiological conditions, the erythrocyte senses oxygen partial pressure (PaO2) in the vasculature 
scavenging both oxygen and nitric oxide in higher PaO2 or delivering them in lower PaO2 (NO) [87]. 
The capture and donation of both gases is dependent on the haemoglobin (Hb) conformation states 
being its relaxed state is associate with scavenging and its tense state with both gases donation [88,89]. 
Erythrocytes mediate the availability of NO and collection to and from the endothelium [87].  
This recruiting cycle, reservation and donation of NO by erythrocyte applies to both NO synthesized in 
the lung or inhaled [87]. 
Previous studies have demonstrated the presence of NO inside the erythrocyte using fluorescence 
microscopy [90].The influx of NO to red blood cells occurs through the band 3 protein also known by 
the chloride/bicarbonate anionic channel [91]. The influx depends on the tendency of the band 3 protein 
to adopt the structure of the dimer or the tetramer and on the degree of denaturation of hemoglobin, 
i.e., the presence of Heinz bodies and methemoglobin [92]. The presence of tetramers or methemoglobin 
and Heinz bodies are unfavourable and blocks the entry of NO into erythrocytes [12]. The rate of 
influx in the erythrocytes is higher in the hemoglobin deoxygenated state than in the oxygenated  
state [93]. Conditions of increased hematocrit favor the influx in oxygenated RBCs [93]. 
The erythrocyte acts as a carrier and as a nitric oxide donor. The output of NO from the erythrocytes 
occurs through the band 3 protein dependent on its degree of phosphorylation [94]. The molecular 
forms of NO, namely the nitrosilhemoglobin (NO bound to heme iron of hemoglobin) the 
nitrosohemoglobin (NO bind to the thiol group of cysteine 93 of the beta chain of hemoglobin) and 
nitrosoglutathione regulate the availability of NO by erythrocyte [95]. 
Glutathione is an abundant molecule inside erythrocytes which has a thiol group that can react with 
nitric oxide, forming nitrosothiols such as S-nitrosoglutathione (GSNO) [96]. The NO reservoir 
attributed to glutathione could be influenced by the inactivation of glutathione reductase induced by 
oxidative stress [97]. The thiol/disulfide reagents such as reduced or oxidized gluthathione (which are 
present at high levels inside RBCs), have a suitable redox potential that is useful for protein 
regeneration. For instance, dithiothreitol (DTT) is a thiol-reducing agent capable of regenerating 
disulfide-containing proteins and also able to establish interchangeable thiol-disulfide reactions with 
glutathione [98]. The presence of DTT induces erythrocyte changes in enzymatic activity states for 
example in protein tyrosine phosphatase (PTP) and protein tyrosine kinase (PTK) [99,100]. DTT 
significantly mobilizes erythrocyte NO to generate nitrites/nitrates and SNOHb, thereby decreasing 
NO efflux [100]. Using the same experimental model, DTT was proven to enhance the levels of 
GSNO, nitrite/nitrate concentrations [101]. 
When auto-oxidation of hemoglobin occurs, it produces peroxide anion which generates 
peroxynitrite after reacting with NO [102]. The decomposition of peroxynitrite molecules yields nitrite 
and nitrate [103] and the reaction between peroxynitrite and hemoglobin generates SNOHb, which 
could decompose to nitrosothiol and nitrate [104]. However, NO may reduce oxyhemoglobin to 
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methemoglobin along with the formation of nitrate without any variation in the methemoglobin 
concentration [104,105]. This could be associated with the presence of hemoglobin reductase coupled 
with NADH that is produced in the glycolytic pathway [106]. In vitro, the NO donor, Spermine 
NONOate, induces an increase in the methemoglobin concentration and decreases the P50 values, which 
means that hemoglobin oxygen affinity increases [105].  
An electrochemical method was described for quantification of the efflux of NO from erythrocytes 
using an NO electrode sensor in erythrocyte suspensions containing acetylcholine [16]. Further studies 
documented a signal transduction mechanism in erythrocytes involving the AChE-acetylcholine 
(active enzyme—substrate complex), the Gi protein, the band 3 protein—dependent of the degree of 
phosphorylation [107,108]. In the presence of velnacrine, an inactive enzyme complex is formed  
and lower levels of erythrocyte efflux were observed than those obtained in the presence of  
acetylcholine [107,108]. Timolol is an inhibitor of erythrocyte AChE [109] and does not change 
erythrocyte NO bioavailability in erythrocyte suspensions [110]. This can be considered an advantage 
if the vascular lumen is under high levels of reactive oxygen species, as the formation of  
peroxinitrite will not be favored. The antioxidant properties of timolol have been reported in vivo and  
in vitro [111–113]. 
The erythrocyte scavenging property of NO is preserved by fibrinogen binding to the RBC 
membrane [114]. The same was verified mimicking hiperfibrinogenemia conditions in the absence or 
presence of acetylcholine [115,116]. However, a reverse situation is obtained when higher fibrinogen 
concentrations are simultaneously present with phosphorylation of band 3 protein [115]. This result 
could be considered a useful therapeutic tool in blood storage for further transfusion. Fibrinogen binds 
to the erythrocyte membrane CD47 and when the agonist peptide of CD47 is added to erythrocytes, the 
same NO scavenging property was verified [117]. 
High NO release from RBC samples was observed in vitro from patients with hypoxia and 
inflammatory states, namely sickle cell disease, hypercholesterolemic, and hypertensive patients; also, 
impairment in erythrocyte deformability was documented [118].  
Vasoconstriction and ischemia may occur when patients are submitted to blood transfusions 
originating from blood-bank-stored blood, which have a lower ability to release both oxygen and  
NO [119]. NO consumption by erythrocytes is regulated under hypoxic conditions by deoxygenated 
Hb that binds to iron heme (NO occupies the vacant site left by oxygen). The NO-heme hemoglobin 
adduct (HbFe (II) NO) has been detected during NO inhalation therapy used for pulmonary 
hypertension treatment, but it also occurs when deoxygenated blood enters a vascular bed in which NO 
is produced, such as the pulmonary circulation [120,121]. In situations of hyperemia, the nitrosylated 
hemoglobin recently measured in vivo by a modified subtraction method using electron paramagnetic 
resonance correlated with the endothelium function measured by tonometry [122]. Under hypoxic 
conditions established in vitro in segments of mesentery arteries of Wistar rats perfused with erythrocyte 
suspensions vasodilation occurs due to the liberation of NO from erythrocyte in dependence of the 
shear stress [123]. 
Inducible NOS expression in the endothelium increases in ischemia/hypoxia conditions or 
ischemia/reperfusion in which blood flow decreases, thereby favoring HbFe (II) NO formation [124]. 
From all these results, the use of NO donors must be accompanied by NO in situ monitoring with a 
microelectrode sensor.  
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6. Conclusions 
Nitric oxide is a signaling molecule influential in several vascular diseases. By NOS uncoupling, 
NO lowers its levels and endothelial dysfunction is installed. The endothelial dysfunction generates 
reactive oxygen species that impair the NO concentration by its combination with superoxide anion. 
The tendency to apply NO donors seems to be the choice for monitoring the therapeutic option. 
However, care must be taken with NO measurements in situ resulting in the expression of the inducible 
NOS. The availability of erythrocyte to scavenge or release NO, measured using a microelectrode 
sensor, is a reflex also of the endothelium and recommended to monitor cardiovascular disease.  
The signal transduction mechanisms evidenced for the ACh–AChE active complex can be a routed for 
therapeutic control of NO bioavailability of the erythrocyte. The electrochemical sensors are well 
established class of in vivo sensors, which offer almost real-time NO determinations 
Acknowledgments 
This study was supported by grants from the FCT—Fundação para a Ciência e a Tecnologia 
(project reference EXCL/Mat-NAN/0114/2012). 
Author Contributions 
The co-authors contribute with their technical expertise on the research published papers here 
referenced and with the revision of this paper. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Palmer, R.M.J.; Ashton, D.S.; Moncada, S. Vascular endothelium cells synthesize nitric oxide 
from L-arginine. Nature 1988, 333, 664–666. 
2. Michel, T.; Feron, O. Nitric oxide synthase: Which, where, how and why? J. Clin. Invest. 1997, 
100, 2146–2152. 
3. Ignarro, L.J. Nitric oxide as a unique signaling molecule in the vascular system: A historical 
overview. J. Physiol. Pharmacol. 2002, 53, 503–514. 
4. Griffith, O.W.; Stuehr, D.J. Nitric oxide synthases: Properties and catalytic mechanism.  
Ann. Rev. Physiol. 1995, 57, 707–736. 
5. Guzik, T.J.; West, N.E.J. Vascular superoxide production by NAD(P)H oxidase: Association 
with endothelium dysfunction and clinical risk factors. Circ. Res. 2000, 86, e85–e90. 
6. Ramndriamboavony, V.; Fleming, I. Endothelial nitric oxide synthase (eNOS) in platelets: How 
is regulated and what is it doing there? Pharmacol. Rep. 2005, 57 (Suppl.), 59–65. 
7. Bloch, K.D.; Janssens, S. Cardiomyocyte-specific overexpression of nitric oxide synthase 3: 
Impact on left ventricular function and myocardial infarction. Trends Cardiovasc. Med. 2005, 15, 
249–253. 
Biosensors 2014, 4 10 
 
 
8. Liao, J.C.; Hein, T.W.; Vaughn, M.W.; Huang, K.T. Intravascular flow decreases erythrocyte 
consumption of nitric oxide. Proc. Nat. Acad. Sci. USA 1999, 96, 8757–8761. 
9. Lugnier, C.; Keravis, T.; Eckly-Mychel, A. Cross talk between NO and cyclic nucleotide 
phosphodiesterases in the modulation of signal transduction in blood vessel. J. Physiol. 
Pharmacol. 1999, 50, 639–652. 
10. Pries, A.R.; Kuebler, W.M. Normal endothelium. Hand. Exp. Pharmacol. 2006, 176, 1–40. 
11. Singh, D.K.; Winocour, P.; Farringhton, K. Endothelial cell dysfunction, medial arterial 
calcification and osteoprotegerin in diabetes. Brit. J. Diab. Vasc. Dis. 2010, 10, 71–77. 
12. Wadsworth, R.; Stankevicius, E.; Simonsen, U. Physiologically relevant measurements of nitric 
oxide in cardiovascular research using electrochemical microsensors. J. Vasc. Res. 2006, 43,  
70–85. 
13. Hall, C.N.; Garthwaite, J. What is the real physiological NO concentration in vivo? Nitric Oxide 
2009, 21, 92–103. 
14. Takarada, S.; Imanishi, T.; Goto, M.; Mochizuki, S.; Ikejima, H.; Tsujioka, H.; Kuroi, A.; 
Takeshita, T.; Akasaka, T. First evaluation of real-time nitric oxide changes in the coronary 
circulation in patients with non-ischaemic dilated cardiomyopathy using a catheter-type sensor. 
Eur. Heart J. 2010, 31, 2862–2870. 
15. Zang, X. Real time and in vivo monitoring of nitric oxide by electrochemical sensors—From 
dream to reality. Front Biosci. 2004, 1, 3434–3446. 
16. Carvalho, F.A.; Martins-Silva, J.; Saldanha, C. Amperometric measurements of nitric oxide in 
erythrocytes. Biosens. Bioelectron. 2004, 20, 505–508. 
17. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2, 907–916. 
18. Malinski, T.; Taha, Z. Nitric oxide release from a single cell measured in situ by a  
porphyrinic-based microsensor. Nature 1992, 358, 676–678. 
19. Casero, E.; Pariente, F.; Lorenzo, E.; Beyer, L.; Losada, J. Electrocatalytic oxidation of nitric 
oxide at 6,17-diferrocenyldibenzo[b,i]5,9,14,18-tetraaza[14]annulen-nickel(II) modified electrodes. 
Electroanalysis 2001, 13, 1411–1415. 
20. Ciszewski, A.; Milczarek, G. Electrochemical detection of nitric oxide using polymer modified 
electrodes. Talanta 2003, 61, 11–26. 
21. Bedioui, F.; Villeneuvre, N. Electrochemical nitric oxide sensors for biological samples-principle, 
selected examples and applications. Electroanalysis 2003, 15, 5–18. 
22. Bedioui, F.; Trevin, S.; Albin, V.; Villegas, M.G.G.; Devynck, J. Design and characterization of 
chemically modified electrodes with iron(III) porphyrinic-based polymers: Study of their reactivity 
toward nitrites and nitric oxide in aqueous soulution. Anal. Chim. Acta. 1997, 341, 177–185. 
23. Diab, N.; Schuhmann, W. Electropolymerized manganese porphyrin/polypyrrole films as catalytic 
surfaces for the oxidation of nitric oxide. Electrochim. Acta. 2001, 47, 265–273. 
24. Liu, X.J.; Shang, L.B.; Pang, J.T.; Li, G.X. A reagentless nitric oxide biosensor based on 
haemoglobin/polyethyleneimine film. Biotechnol. Appl. Biochem. 2003, 38, 119–122. 
25. Markus, M.; Pariente, F.; Wu, Q.; Toffanin, A.; Shapleigh, J.P.; Abruna, H.D. Electrocatalytic 
reduction of nitric oxide at electrodes modified with electropolymerized films of [Cr(v-tpy)2]
3+
 
and their application to cellular NO determinations. Anal. Chem. 1996, 68, 3128–3134.  
Biosensors 2014, 4 11 
 
 
26. Meulemans, A. Continuous monitoring of N-nitroso-L-arginine using micro carbon electrode in 
rat brain. Neurosci. Lett. 1993, 157, 7–12. 
27. Shin, J.H.; Privett, B.J.; Kita, J.M.; Wightman, R.M.; Schoenfisch, M.H. Fluorinated  
Xerogel-derived microelectrodes for amperometric nitric oxide sensing. Anal. Chem. 2008, 80, 
6850–6859. 
28. Kitamura, Y.; Uzawa, T.; Oka, K.; Komai, Y.; Ogawa, H.; Talizawa, N.; Kobayashi, H.; 
Tanishita, K. Microcoaxial electrode for in vivo nitric oxide measurement. Anal. Chem. 2000, 72, 
2957–2962. 
29. Mao, L.Q.; Yamamoto, K.; Zhou, W.L.; Jin, L.T. Electrochemical nitric oxide sensors based on 
electropolymerized film of M(salen) with central ions of Fe, Co, Cu, and Mn. Electroanalysis 
2000, 12, 72–77. 
30. Shibuli, K. An electrochemical microprobe for detecting nitric oxide release in brain tissue. 
Neurosci. Res. 1990, 9, 69–76. 
31. Vallance, P.; Patton, S.; Bhagat, K.; Macallister, R.; Radomski, M.; Moncada, S.; Malinski, T. 
Direct measurement of nitric oxide in human beings. Lancet 1995, 346, 153–154. 
32. Brovlkovych, V.; Stolarczyk, E.; Oman, J.; Tomboulian, P.; Malinski, T.J. Direct electrochemical 
measurement of nitric oxide in vascular endothelium. Pharm. Biomed. Anal. 1999, 19, 135–143. 
33. Brown, F.O.; Finnerty, N.J.; Lowry, J.P. Nitric oxide monitoring in brain extracellular fluid: 
Characterization of Nafion
®
-modified Pt electrodes in vitro and in vivo. Analyst 2009, 134, 
2012–2020. 
34. Griveau, S.; Dumezy, C.; Seguin, J.; Chabot, G.G.; Sherman, D.; Bedioui, F. In vivo 
electrochemical detection of nitric oxide in tumor-bearing mice. Anal. Chem. 2007, 79, 1030–1033. 
35. Dormandy, J.; Ernst E.; Matrai, A.; Flute, P.T. Hemorrheological changes following acute 
myocardial infarction. Am. Heart J. 1982, 104, 1364–1367. 
36. Gaimi, G.; Serra A.; Presti, C.R.L.; Sarno, A.; Gerasola, G. Red cell metabolic parameters 
rheological determinants in essential hypertension. Clin. Hemorheol. 1993, 13, 35–44. 
37. Jay, R.H.; Rampling, M.W.; Betteridge, D.J. Abnormalities of blood rheology in familial 
hypercholesterolemia: Effects of treatment. Atherosclerosis 1990, 85, 249–256. 
38. Khodabandehlou, T.; Le Deveat, C.; Razavian, M.; Boynard, M. Functional capacity of 
fibrinogen and erythrocyte aggregation in the diabetic. J. Mal. Vasc. 1994, 19, 278–282. 
39. Félétou, M.; Köhlerm, R.; Vanhoute, P.M. Endothelium-derived vasoactive factors and 
hypertension: Possible roles in pathogenesis and as treatment targets. Curr. Hypertens. 2010, 12, 
267–275. 
40. Vanhoute, P.M. Endothelial dysfunction the first step toward coronary arteriosclerosis. Circ. J. 
2009, 73, 595–601. 
41. Griendling, K.K.; Sorescu, D.; Ushio-Fucai, M. NAD(P)H oxidase: Role in cardiovascular biology 
and disease. Circ. Res. 2000, 86, 494–501. 
42. Sorecu, D.; Weiss, D.; Lassegue, B.; Campus, R.E.; Szocs, K.; Sorecu, G.P.; Valppu, L.;  
Quinn, M.T.; Lambeth, J.D.; Veja, J.D.; Taylor, W.R.; Griendling, K.K. Superoxide production 
and expression of Nox family proteins in human atherosclerosis. Circulation 2002, 105,  
1429–1435. 
Biosensors 2014, 4 12 
 
 
43. Li, H.; Wallerath, T.; Münze, T.; Förstermann, U. Regulation of endothelial-type NO synthase 
expression in pathology and I response to drugs. Nitric Oxide Biol. Chem. 2002, 7, 149–164. 
44. Drummond, G.R.; Cai, H.; Davies, M.E.; Ramasamy, S.; Harrison, D.G. Transcriptional and 
posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen 
peroxide. Circ. Res. 2000, 86, 347–354. 
45. Ludewig, B.; Zinkernagel, R.M.; Hengar, T.H. Arterial inflammation and atherosclerosis. Thends 
Cardiovasc. Med. 2002, 12, 154–159. 
46. Sogo, N.; Magid, K.S.; Shawca, C.A.; Webb, D.Y.; Meyson, I.L. Inhibition of human platelet 
aggregation by nitric oxide donor drugs: Relative contribution of cGMP-independent mechanism. 
Biochem. Biophys. Res. Commum. 2000, 279, 412–419. 
47. Wang, B.Y.; Ho, H.K,; Lin, P.S.; Pollman, M.J.; Gibbons, G.H.; Tsao, P.S.; Cooke, J.P. 
Regression of atherosclerosis: Role of nitric oxide and apoptosis. Circulation 1999, 99,  
1236–1241. 
48. Kocks, M.M.; Knaapen, M.W. The role of apoptosis in vascular disease. J. Pathol. 2000, 190, 
267–280. 
49. Napoli, C.; Ignaro, L.I. Nitric oxide and pathogenic mechanisms involved in development of 
vascular disease. Arch. Pharm. Res. 2009, 32, 1103–1108. 
50. Lyamina, N.P.; Lyamina, S.V.; Senchiknin, V.N.; Mallet, R.T.; Downey, H.F.; Manukhina, E.B. 
Normobaric hypoxi conditioning reduces blood pressure and normalizes nitric oxide synthesis in 
patients with arterial hypertension. J. Hypertens. 2011, 29, 2265–2272. 
51. Moya, M.P.; Gow, A.J.; Califf, R.M.; Goldberg, R.N.; Stamler, J.S. Inhalated ethyl nitrite gas for 
persistent pulmonary hypertension of the newborn. Lancet 2002, 360, 141–143. 
52. Wilkins, M.R.; Aldashev, A.; Morrell, N.W. Nitric oxide, phosphodiesterase inhibition and 
adaptation to hypoxic conditions. Lancet 2002, 359, 539–1540. 
53. Gosh, R.; Sawant, O.; Ganpathy, P.; Pitre, S.; Kadam, V.J. Posphodiesterase inhibitors: Their 
role and implications. Int. J. Pharm. Tech. Res. 2009, 1, 1148–1160. 
54. Herman, A.G.; Moncada, S. Therapeutic potential of nitric oxide donors in prevention and 
treatement of atherosclerosis. Eur. Heart. J. 2005, 26, 1945–1955. 
55. Lundberg, J. Nitric oxide metabolites and cardiovascular disease markers, mediators, or both?  
J. Am. Coll. Cardiol. 2006, 47, 580–581. 
56. Wallace, J.I.; Ignarro, L.J.; Fiorucci, S. Potential cardioprotective actions of NO-releasing 
aspirin. Nat. Rev. Drug Discov. 2002, 1, 375–382. 
57. Lazzarato, L.; Donnola, M.; Rolando, B.; Chegaev, K.; Marini, E.; Cena, C.; Di Stilo, A.; 
Fruttero, R.; Biondi, S.; Ongini, E.; Gasco, A. Nitrooxyacyloxy methyl esters of aspirin as novel 
nitric oxide releasing aspirins. J. Med. Chem. 2009, 52, 5058–5068. 
58. Förstermann, U. Nitric oxide and oxidative stressing vascular disease. Pflügers Arch. Eur. J. 
Physiol. 2010, 459, 923–939. 
59. Dal-Ros, S.; Zoll, J.; Lang, A.L.; Auger, C.; Keller, N.; Bronner, C.; Geny, B.; Schini-Kerth, V.B. 
Chronic intake of red wine polyphenols by young rats prevents aging-induced endothelial 
dysfunction and decline in physical performance: Role of NADPH oxidase. Biochem. Biophys. 
Res. Commun. 2011, 401, 743–749. 
Biosensors 2014, 4 13 
 
 
60. Pinto, V.; Brunini, T.; Ferraz, M.R.; Okinga, A.; Mendes-Ribeiro, A.C. Depression and 
cardiovascular disease: Role of nitric oxide. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 
142–149. 
61. Kapil, V.; Webb, A.J.; Ahluwalia, A. Iinorganic nitrate and the cardiovascular system. Heart 
2010, 96, 1703–1709. 
62. Tang, Y.; Jiang, H.; Bryan, N.S. Nitrite and nitrate: Cardiovascular risk-benefit and metabolic 
effect. Curr. Opin. Lipid. 2011, 22, 11–15. 
63. Blakenberg, S.; Rupprecht, H.J.; Bickel, C.; Torzewski, M.; Hafner, G. Tiret, L.; Smieja, M.; 
Cambiem, F.; Meyer, J.; Lackner, K.J.; for the AtheroGene Investigators. Gluthathione 
peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. 
J. Med. 2003, 349, 1605–1613. 
64. Bhandary, U.; Tse, W.; Yang, B.; Knowles, M.R.; Demaine, A.G. Endothelial nitric oxide 
synthase polymorphisms are associated with hypertension and cardiovascular disease in renal 
transplantation. Nephrology 2008, 13, 348–355. 
65. Mollsten, A.; Lajer, M.; Jorsal, A.; Tamow, L. The endothelial nitric oxide synthase gene and 
risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes.  
Mol. Gen. Metab. 2009, 97, 80–84. 
66. Carvalho, F.A; Saldanha, C.; Silva, J.M.E. Doseamento electroquímico do monóxido de azoto 
em células endotelias humans. RFML 2003, 8, 205–212. 
67. Travers, J.P.; Brookes, C.E.; Evan, J.; Baker, D.M.; Kent, C.; Makin, G.S.; Mayhew, T.M. 
Assessment of wall structure and composition of varicose vein with reference to collagen, elastin 
and smooth muscle content. Eur. J. Vasc. Endovasc. Surg. 1996, 11, 230–237. 
68. Venturi, M.; Bonavina, L.; Annoni, F.; Colombo, L.; Butera, C.; Peracchia, A.; Mussini, E. 
Biochemical assay of collagen and elastin in the normal and varicose vein wall. J. Surg. Res. 
1996, 60, 245–248. 
69. Michiels, C.; Arnould, T.; Knott, I.; Dieu, M.; Remacle, J. Stimulation of prostaglandin synthesis 
by human endothelial cells exposed to hypoxia. Am. J. Physiol. 1993, 264, C866–C874.  
70. Michiels, C.; Arnould, T.; Remacle, J. Hypoxia-induced activation of endothelial cells as a 
possible cause of venous diseases: Hypothesis. Angiology 1993, 44, 639–646. 
71. Michiels, C.; Bouaziz, N.; Remacle, J. Role of the endothelium and blood stasis in the 
development of varicose veins. Int. Angiol. 2002, 21, 18–25.  
72. Michiels, C.; Renard, P.; Bouaziz, N.; Heck, N.; Eliaers, F.; Ninane, N.; Quarck, R.; Holvoet, P.; 
Raes, M. Identification of the phospholipase A2 isoforms that contribute to arachidonic acid 
release in hypoxic endothelial cells: Limits of phospholipase A2 inhibitors. Biochem. Pharmacol. 
2002, 63, 321–332. 
73. Schmid-Schönbein, G.W. Inflammation and the pathophysiology of chronic venous insufficiency. 
Phlebolymphology 2003, 39, 95–99. 
74. Eriksson, E.E.; Karlov, E.; Lundmark, K.; Rotzius, P.; Hedin, U.; Xie, X. Powerful inflammatory 
properties of large vein endothelium in vivo. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 723–728. 
75. Migliacci, R.; Becattini, C.; Pesavento, R.; Davi, G.; Vedovati, M.C.; Guglielmini, G.;  
Falcinelli, E.; Ciabattoni, G.; Valle, F.D.; Prandoni Pagnelli, G.; Gresele, P. Endothelial dysfunction 
in patients with spontaneous venous thromboembolism. Hemathology J. 2007, 92, 812–818. 
Biosensors 2014, 4 14 
 
 
76. Blackman, D.J.; Morris-Thurgood, J.Á.; Atherton, J.J.; Ellis, G.R.; Anderson, R.A.; Cokcroft, J.R.; 
Frenneaux, M.P. Endothelium-derived nitric oxide contributes to the regulation of venous tone in 
humans. Circulation 2000, 101, 165–170.  
77. Martini, J.; Carpentier, B.; Chávez Negrete, A.; Cabrales, P.; Tsai, A.G.; Intaglietta, M. 
Benefitial effects due to increasing blood and plasma viscosity. Clin. Hemorheol. Microcirc. 2006, 
35, 51–57. 
78. Ahmed, E.T.; Maayah, M.F.; Asi, Y. Anodyne therapy versus exercise therapy in improving the 
healing rates of venous leg ulcer. Int. J. Res. Med. Sci. 2013, 13, 198–203. 
79. Foutaine, M.F.; Raduolovic M.C.; Cardozo, C.P.; Spungen, A.M.; DeMeersman, R.E.;  
Bauman, W.A. Effects of acute nitric oxide synthase inhibition on lower leg vascular function in 
chronic tetraplegia. J. Spinal Cord. Med. 2009, 32, 538–544. 
80. Mortensen, S.; Askew, C.D.; Walker, M.; Nyberg, M.; Hellesten, Y. The hyperaemic response to 
passive leg movement is dependent on nitric oxide; a new tool to evaluate endothelial nitric oxide 
function. J. Physiol. 2012, 590, 4391–4000. 
81. Esper, R.J.; Nordaby, R.A.; Vilarino, J.O.; Paragano, A.; Cacharrón, J.L.; Machado, R.A. 
Endothelial dysfunction: A comprehensive appraisal. Cardiovasc. Diabetol. 2006, 5, 
doi:10.1186/1475-2840-5-4.  
82. Vujanac, A.; Jakovljevic, V.; Djordevic, D.; Zivkovic, V.; Stojlovic, M.; Celikovic, N.;  
Skevin, A.J.; Djuric, D. Nitroglycerine effects on portal vein mechanics and oxidative stress in 
portal hypertension. World Gastroenterol. 2012, 18, 331–339. 
83. Burroughs, A.K.; Thalheimer, U. Hepatic venous pressure gradient in 2010: Optimal measurement 
is key. Hepatology 2010, 51, 1894–1896  
84. Rockey, D.C. Hepatic fibrosis, stellate cells, and portal hypertension. Clin. Liver Dis. 2006, 10, 
459–479. 
85. Iwakiri, Y.; Groszmann, R.J. Vascular endothelial dysfunction in cirrhosis. J. Hepatol. 2007, 46, 
927–934.  
86. Zafra, C.; Abraldes, J.G.; Turnes, J.; Berzigotti, A.; Fernández, M.; Garca-Pagán, J.C.; Rodés, J.; 
Bosch, J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular 
tone in patients with cirrhosis. Gastroenterology 2004, 126, 749–755.  
87. MacMahomn, T.; Doctor, A. Extrapulmonary effects of inhalated nitric oxide. Proc. Am. Thorac. 
Soc. 2006, 3, 153–160. 
88. Lane, P.; Gross, S. Hemoglobin as a chariot for NO bioactivity. Nature Med. 2002, 8, 657–658. 
89. Jia, L.; Bonaventura, J.; Stamler, J.S. S-nitrosohaemoglobin: A dynamic activity of blood 
involved in vascular control. Nature 1996, 380, 221–226. 
90. Mesquita, R.; Martins-Silva, J.; Saldanha, C. Acetylcholine induces nitric oxide production by 
erythrocytes in vitro. Nitric Oxide Biol. Chem. 2000, 177, 313–314. 
91. Han, T.H.; Qamirani, E.; Nelson, A.G.; Hyduke, D.R.; Chaudhuri, G.; Kuo, L.; Liao, J.C. 
Regulation of nitric oxide consumption by hypoxic red blood cells. Proc. Nat. Acad. Sci. USA 
2003, 100, 12504–12509. 
92. Huang, K.T.; Han, T.H.; Hyduke, D.R.; Vaughn, M.W.; Herle, H.V.; Hein, T.W.; Zang, C.;  
Kuo, L.; Liao, J.C. Modulation of nitric oxide bioavailability by erythrocytes. Proc. Nat. Acad. 
Sci. USA 2001, 98, 11771–11775. 
Biosensors 2014, 4 15 
 
 
93. Azarov, I.; Huang, K.T.; Basu, S.; Gladwin, M.T.; Hog, N.; Kim-Shapiro, D.B. Nitric oxide 
scavenging by red blood cells as a function of hematocrit and oxygenation. J. Biol. Chem. 2005, 
280, 19024–19032. 
94. Pawloski, J.R. Hess, D.T. Stamler, J.S. Impaired vasodilation by red blood cells in sickle cell 
disease. Proc. Nat. Acad. Sci. USA 2005, 10, 2531–2536. 
95. Chen, K.; Popel, A.S. Nitric oxide productions pathways in erythrocyte and plasma. Biorheology 
2009, 46, 107–119. 
96. Galli, F.; Rossi, R.; Di Simplicio, P.; Floridi, A.; Canestrari, A. Protein thiols and glutathione 
influence the nitric oxide-dependent regulation of the red blood cell F metabolism. Nitric Oxide 
2002, 6, 186–199. 
97. Fujii, T.; Hamaoka, R.; Fujii, J.; Taniguchi, N. Redox capacity of cells affects inactivation of 
glutathione reductase by nitrosative stress. Archives Biochemical. Biophysica 2000, 378, 123–130. 
98. Rothwarf, D.M.; Scheraga, H.A. Equilibrium and kinetic constants for the thiol-disulfide 
interchange reaction between glutathione and dithiothreitol. Proc. Nat. Acad. Sci. USA 1992, 89, 
7944–7948. 
99. Zipser, Y.; Piade, A.; Kosower, N.S. Erythrocyte thiol status regulates band 3 phosphotyrosine 
level via oxidation/reduction of band 3-associated phosphotyrosine phosphatase. FEBS Lett. 
1997, 406, 126–130. 
100. Lopes de Almeida, J.P.; Carvalho, F.A; Silva-Herdade, A.S; Santos-Freitas, T. Saldanha, C. 
Redox thiol status plays a central role in the mobilization and metabolism of nitric oxide in 
human red blood cells. Cell Biol. Inter. 2009, 33, 268–275. 
101. Lopes de Almeida, J.P.; Freitas-Santos, T.; Saldanha, C. Fibrinogen-dependent signalling 
microvascular erythrocyte function: Implications on nitric oxide efflux. J. Membr. Biol. 2009, 
231, 47–53. 
102. Balagopalakrishna, C.; Manoharan, P.T.; Abugo, O.O.; Rifkind, J.M. Production of superoxide 
from hemoglobin-bound oxygen under hypoxic conditions. Biochemistry 1996, 35, 6393–6398. 
103. Pfeiffer, S.; Mayer, B. Lack of tyrosine nitration by peroxynitrite generated at physiological pH. 
Biol. Chem. 1998, 273, 27280–27285. 
104. Gladwin, M.T.; Wang, X.; Reiter, C.D. SNitrosohemoglobin is unstable in the reductive 
erythrocyte environment and lacks O2/NO-linked allosteric function. J. Biol. Chem. 2002, 277, 
27818–27828. 
105. Mesquita, R.; Pires, I.; Saldanha, C.; Martins-Silva, J. Effects of acetylcholine and 
spermineNONOate on erythrocyte hemorheologic and oxygen carrying properties. Clin. 
Hemorheol. Microcirc. 2001, 25, 153–163. 
106. Inal, M.E.; Egüz, A.M. The effects of isosorbide dinitrate on methemoglobin reductase enzyme 
activity and antioxidant states. Cell Biochem. Funct. 2004, 22, 129–133. 
107. Carvalho, F.A.; Almeida, J.P.; Fernandes, I.O.; Freitas-Santos, T.; Saldanha, C. Non-neuronal 
cholinergic system and signal transduction pathways mediated by band 3 in red blood cells.  
Clin. Hemorheol. Microcirc. 2008, 40, 207–227. 
108. Carvalho, F.A.; Lopes de Almeida, J.P.; Freitas-Santos, T.; Saldanha, C. Modulation of 
erythrocyte acetylcholinesterase activity and its association with G protein band 3 interactions.  
J. Membrane Biol. 2009, 228, 89–97. 
Biosensors 2014, 4 16 
 
 
109. Zabala, L.; Saldanha, C.; Martins-Silva, J.; Souza-Ramalho, P. Red blood cell membrane 
integrity in primary open angle glaucoma: ex vivo and in vitro studies. Eye 1999, 13, 101–103. 
110. Saldanha, C.; Teixeira, P.; Santos-Freitas, T.; Napoleão, P. Timolol modulates erythrocyte nitric 
oxide bioavailability. J. Clin. Exp. Ophtalmol. 2013, 4, doi:10.4172/2155-9570.1000285. 
111. Izzotti, A.; Saccà, S.C.; Di Marco, B.; Penco, S.; Bassi, A.M. Antioxidant activity of timolol on 
endothelial cells and its relevance for glaucoma course. Eye 2008, 22, 445–453. 
112. Djanani, A.; Kaneider, N.C.; Meierhofer, C.; Sturn, D.; Dunzendorfer, S. Allmeier, H.; 
Wiedermann, C.J. Inhibition of neutrophil migration and oxygen free radical release by 
metipranolol and timolol. Pharmacology 2003, 68, 198–203. 
113. Ricci, B.; Minicucci, G.; Manfredi, A.; Santo, A. Oxygen-induced retinopathy in the newborn 
rat: Effects of hyperbarism and topical administration of timolol maleate. Graefe’s Arch. Clin. 
Exp. Ophthalmol. 1995, 233, 226–230. 
114. Lopes de Almeida, J.P.; Freitas-Santos, T.; Saldanha, C. Fibrinogen-dependent signaling in 
microvascular erythrocyte function: Implications on nitric oxide flux. J. Membrane Biol. 2009, 
231, 47–53. 
115. Lopes de Almeida, J.P.; Freitas-Santos, T.; Saldanha, C. Evidence that the degree of band 3 
phosphorylation modulates human erythrocytes nitric oxide efflux—In vitro model of 
fibrinogenemia. Clin. Hemorheol. Microcirc. 2011, 49, 407–416. 
116. Saldanha C; Freitas-Santos, T.; Lopes de Almeida, J.P. Fibrinogen effects on erythrocyte nitric 
oxide mobilization in presence of acetylcholine. Life Sci. 2012, 91, 1017–1022. 
117. Saldanha, C.; Freitas-Santos, T.; Lopes de Almeida, J.P. CD47 Agonist Peptide Effects on 
Human Erythrocyte Nitric Oxide Mobilization in Presence of Fibrinogen Poster Presentation 
(P002). In Program and Abstract Book; In Proceedings of XXIInd International Fibrinogen 
Workshop, Brighton, UK, 4–6 July 2012; p. 77. 
118. Carvalho, F.A.; Maria, A.V.; Braz Nogueira, J.; MGuerra, J.; Martins-Silva, J.; Saldanha, C.  
The relation between the erythrocyte nitric oxide and hemorheological parameters. Clin. 
Hemorheol. Microcirc. 2006, 35, 341–347. 
119. Bonaventura, J. Clinical implications of the loss of vasoactive nitric oxide during red blood cell 
storage. Proc. Nat. Acad. Sci. USA 2007, 104, 19165–19166. 
120. Ignarro, L.; Byrns, J.R.E.; Buga, G.M.; Wood, S.K. Endothelium-derived relaxing factor from 
pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of 
nitric oxide radical. Circ. Res. 1987, 61, 866–879. 
121. Cannon, R.R.O., III.; Schechter, A.N.; Panza, J.; Ognibene, F.P.; Pease-Fye, M.E.;  
Waclawiw, M.A.; Shelhamer, J.H.; Gladwin, M.T. Effects of inhaled nitric oxide on regional 
blood flow are consistent with intravascular nitric oxide delivery. J. Clin. Invest. 2001, 108,  
279–287. 
122. Lobysheva, I.; Biller, P; Gallez, B; Beauloye, C; Balligand, J. Nitrosylated Hemoglobin levels in 
human venous erythrocytes correlate with vascular endothelial function measured by digital 
reactive hyperemia. PLoS One 2013, 8, doi:10.1371/journal.pone.0076457. 
123. Ulker, P.; Gunduz, F.; Meiselman, H. J.; Baskurt, O.K. Nitric oxidegenerated by red blood cells 
following exposure to shear stress dilates isolated small mesenteric arteries under hypoxic 
conditions. Clin. Hemorheol. Microcirc. 2013, 54, 357–369. 
Biosensors 2014, 4 17 
 
 
124. Battista, S; Mengozzi, G.; Bar, F.; Cerutti, E.; Pollet, C.; Torchio, M.; Biasi, F.; Cavalli, G.; 
Sallizoni, M.; Poli, G.; Molino, G. Nitric oxide level profile in human liver transplantation. 
Digest. Dis. Sci. 2002, 47, 528–534. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
